Voyager Therapeutics (VYGR) Net Margin (2015 - 2026)

Voyager Therapeutics has disclosed Net Margin across 12 years of filings, most recently posting 764.78% for Q2 2026.

• In Q2 2026, Net Margin fell 12282.0% year-over-year to 764.78%; the TTM figure through Jun 2026 stood at 238.93% (up 1440.0% YoY), while the FY2025 annual figure was 296.53%, down 21528.0% from the prior year.
• Net Margin came in at 764.78% for Q2 2026 at Voyager Therapeutics, up from 1074.5% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 1524.26% in Q4 2022 to a low of 3239.97% in Q1 2022.
• Average Net Margin over 5 years is 504.59%, with a median of 330.69% recorded in 2023.
• Year-over-year, Net Margin tumbled 284652 bps in 2022 and surged 332240 bps in 2023.
• Over 5 years, Net Margin stood at 1524.26% in 2022, then tumbled by 96 bps to 62.62% in 2023, then slumped by 977 bps to 549.33% in 2024, then surged by 97 bps to 14.44% in 2025, then sank by 5198 bps to 764.78% in 2026.
• Per Business Quant data, the three most recent Net Margin figures were 764.78% in Q2 2026, 1074.5% in Q1 2026, and 14.44% in Q4 2025.